Irinotecan plus cisplatin for the treatment of advanced non-small cell lung cancer / 中华肿瘤杂志
Zhonghua zhong liu za zhi
; (12): 777-779, 2006.
Article
en Zh
| WPRIM
| ID: wpr-316301
Biblioteca responsable:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the efficacy and adverse events of irinotecan (CPT-11) combined with cisplatin (DDP) in the treatment of patients with advanced non-small cell lung cancer (NSCLC).</p><p><b>METHODS</b>Of 36 NSCLC patients consisting of 23 males and 13 females with a medium age of 52 years included, there were 26 adenocarcinomas, 7 squamous cell carcinomas, 1 adeno-squamous cell carcinoma and 2 unclassified types; 13 stage III B and 23 stage IV; 24 chemonaive and 12 previously treated by chemotherapy with a medium Karnofsky status of 90. All patients had measurable or evaluable parameters. The regimen was administered as following: CPT-11 60 mg/m2, IV, D1, 8 and 15; DDP 80 mg/m2, IV, D1; every 28 days as a cycle.</p><p><b>RESULTS</b>Totally, 97 cycles were carried out in these 36 patients with a medium cycles of 3. Of 35 evaluable patients, 22.9% (8/35) achieved partial response, 60.0% (21/35) had stable disease and 17.1% (6/35) progressive disease. The response rate was 29.2% (7/24) for chemonaive patients and 9.1% (1/11) for these previously treated. The 1-year survival rate was 45.4% with a medium time to tumor progression (TTP) of 199 days for the responders. The incidence rate of grade III/IV adverse events were: 16.7% for neutropenia, 13.9% alopecia, 5.6% diarrhea, 2.8% nausea and vomiting, respectively.</p><p><b>CONCLUSION</b>Irinotecan plus cisplatin is effective with tolerable adverse events in treating patients with advanced non-small cell lung cancer, but further investigation trials are needed.</p>
Texto completo:
1
Base de datos:
WPRIM
Asunto principal:
Patología
/
Inducción de Remisión
/
Camptotecina
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Tasa de Supervivencia
/
Mortalidad
/
Cisplatino
/
Carcinoma de Pulmón de Células no Pequeñas
/
Usos Terapéuticos
/
Diarrea
Tipo de estudio:
Prognostic_studies
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
Idioma:
Zh
Revista:
Zhonghua zhong liu za zhi
Año:
2006
Tipo del documento:
Article